David Bahnsen Dividend Strategy
David Bahnsen – founder of The Bahnsen Group and author…
Buy
62
ALKS Quote, Financials, Valuation and Earnings
Last price:
$35.79
Seasonality move
:
-2.82%
Day range:
$35.23 - $36.25
52-week range:
$22.90 - $36.25
Dividend yield:
0%
P/E ratio:
16.54x
P/S ratio:
3.90x
P/B ratio:
3.98x
Volume:
2.6M
Avg. volume:
1.7M
1-year change:
28.22%
Market cap:
$5.8B
Revenue:
$1.6B
EPS (TTM):
$2.17
Analysts' Opinion
-
Consensus RatingAlkermes PLC has received a consensus rating of Buy. The company's average rating is a Buy based on 8 Buy ratings, 4 Hold ratings, and 1 Sell rating.
-
Price Target UpsideAccording to analysts' consensus price target of $36.43, Alkermes PLC has an estimated upside of 1.5% from its current price of $35.89.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $21.00 representing -- downside risk from its current price of $35.89.
Fair Value
-
According to the consensus of 13 analysts, Alkermes PLC has 1.5% upside to fair value with a price target of $36.43 per share.
ALKS vs. S&P 500
-
Over the past 5 trading days, Alkermes PLC has underperformed the S&P 500 by -1.45% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Alkermes PLC does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Alkermes PLC has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Alkermes PLC reported revenues of $430M.
Earnings Growth
-
Alkermes PLC has grown year-over-year earnings for 2 quarters straight. In the most recent quarter Alkermes PLC reported earnings per share of $0.88.
Enterprise value:
5.1B
EV / Invested capital:
0.00x
Price / LTM sales:
3.90x
EV / EBIT:
10.90x
EV / Revenue:
3.26x
PEG ratio (5yr expected):
3.42x
EV / Free cash flow:
12.53x
Price / Operating cash flow:
14.98x
Enterprise value / EBITDA:
10.27x
Gross Profit (TTM):
$1.3B
Return On Assets:
17.19%
Net Income Margin (TTM):
23.57%
Return On Equity:
28.24%
Return On Invested Capital:
23.97%
Operating Margin:
37.84%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $1.1B | $1.7B | $1.6B | $377.5M | $430M | |
| Gross Profit | $893.7M | $1.4B | $1.3B | $307.3M | $367.9M | |
| Operating Income | -$6.1M | $414.1M | $420.6M | $54.6M | $162.7M | |
| EBITDA | $59.8M | $519.5M | $494.9M | $82.9M | $181.4M | |
| Diluted EPS | -$0.96 | $2.07 | $2.17 | $0.66 | $0.88 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $1.1B | $1.1B | $1.1B | $1.5B | $1.4B | |
| Total Assets | $1.9B | $2B | $2B | $2.1B | $2.1B | |
| Current Liabilities | $438.3M | $471.3M | $497.7M | $520.2M | $465.2M | |
| Total Liabilities | $882.7M | $911.9M | $920.2M | $933.5M | $590.6M | |
| Total Equity | $1.1B | $1.1B | $1B | $1.2B | $1.5B | |
| Total Debt | $275M | $295.8M | $293.3M | $290.7M | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $21M | $401.4M | $439.1M | $107.2M | $190.4M | |
| Cash From Investing | -$64.5M | $53.4M | -$111.3M | -$21M | -$13.9M | |
| Cash From Financing | -$1.6M | -$289.7M | -$494.1M | -$276.5M | -$281.7M | |
| Free Cash Flow | -$17.2M | $353.3M | $405.6M | $90.2M | $180.6M | |
ALKS
Sector
Market Cap
$5.8B
$43.9M
Price % of 52-Week High
--
48.46%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.75%
1-Year Price Total Return
28.22%
-34.83%
Beta (5-Year)
0.492
0.748
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$32.88
200-day SMA
Buy
Level
$27.42
Bollinger Bands (100)
Buy
Level
27.41 - 31.13
Chaikin Money Flow
Buy
Level
88.5M
20-day SMA
Buy
Level
$31.78
Relative Strength Index (RSI14)
Buy
Level
78.09
ADX Line
Buy
Level
34.32
Williams %R
Sell
Level
-5.9916
50-day SMA
Buy
Level
$30.54
MACD (12, 26)
Buy
Level
1.20
25-day Aroon Oscillator
Buy
Level
92
On Balance Volume
Neutral
Level
68.1M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (6.1346)
Buy
CA Score
(Annual)
Level (1.4558)
Sell
Beneish M-Score
(Annual)
Level (-2.1336)
Buy
Momentum Score
Level (6)
Buy
Ohlson Score
Level (-3.4408)
Buy
Piotroski F Score
(Annual)
Level (7)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (6)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
Stock Forecast FAQ
In the current month, ALKS has received 8 Buy ratings 4 Hold ratings, and 1 Sell ratings. The ALKS average analyst price target in the past 3 months is $36.43.
-
Where Will Alkermes PLC Stock Be In 1 Year?
According to analysts, the consensus estimate is that Alkermes PLC share price will rise to $36.43 per share over the next 12 months.
-
What Do Analysts Say About Alkermes PLC?
Analysts are divided on their view about Alkermes PLC share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Alkermes PLC is a Sell and believe this share price will drop from its current level to $21.00.
-
What Is Alkermes PLC's Price Target?
The price target for Alkermes PLC over the next 1-year time period is forecast to be $36.43 according to 13 Wall Street analysts, 8 of them rate the stock a Buy, 1 rates the stock a Sell, and 4 analysts rate the stock a Hold.
-
Is ALKS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Alkermes PLC is a Buy. 8 of 13 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ALKS?
You can purchase shares of Alkermes PLC via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Alkermes PLC shares.
-
What Is The Alkermes PLC Share Price Today?
Alkermes PLC was last trading at $35.79 per share. This represents the most recent stock quote for Alkermes PLC. Yesterday, Alkermes PLC closed at $35.89 per share.
-
How To Buy Alkermes PLC Stock Online?
In order to purchase Alkermes PLC stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Netflix a Buy, Sell or Hold?
If there is one company that can be termed a…
Why Is Tesla Stock Falling?
Tesla stock reached an all-time high of $479.86 on December…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 40x
Buy
61
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 116x
Sell
47
Is MSFT Stock a Buy?
Market Cap: $3T
P/E Ratio: 35x
Alerts
Buy
87
PCOR alert for Feb 18
Procore Technologies [PCOR] is up 0.87% over the past day.
Buy
54
DKNG alert for Feb 18
DraftKings [DKNG] is down 3.74% over the past day.
Sell
30
TWLO alert for Feb 18
Twilio [TWLO] is up 0.34% over the past day.
